News Severino takes the helm at Sarepta after turbulent spell Around five months after long-serving CEO Doug Ingram said he was stepping down, Sarepta has named industry veteran Michael Severino to replace him.
News Scribe raises $155m in IPO, as Apnimed pitches for $150m Gene-editing specialist Scribe becomes the 14th biotech to list on the Nasdaq this year, as sleep apnoea drug developer Apnimed prices its listing.
News Is J&J approaching the end of its talc litigation hangover? Johnson & Johnson has made a $5.5bn bid to finally bring more than 15 years of litigation over the safety of its talcum powder products to a close.
News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
News Chris McDonald replaces Vallance as UK science minister Chris McDonald has been named the next UK Minister for Science, following the resignation of Patrick Vallance last week.
News Outlook finally claims FDA approval for AMD drug After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.